References

Diastolic dysfunction in congestive heart failure

10.1056/nejm199111283252206 · 1991 · External reference

Diastolic heart failure – abnormalities in active relaxation and passive stiffness of the left ventricle

10.1056/nejmoa032566 · 2004 · External reference

Hypertensive hypertrophic cardiomyopathy of the elderly

10.1056/nejm198501313120504 · 1985 · External reference

High-sensitivity C-reactive protein in heart failure with preserved ejection fraction

10.1371/journal.pone.0201836 · 2018 · External reference

Interleukin-6 in patients with heart failure and preserved ejection fraction

10.1016/j.jchf.2023.06.031 · 2023 · External reference

What causes inflammation in heart failure and preserved ejection fraction? Potential role of eicosanoid adipokines

10.1016/j.jchf.2025.102638 · 2025 · External reference

Contribution of comorbidities to functional impairment is higher in heart failure with preserved than with reduced ejection fraction

10.1007/s00392-011-0305-4 · 2011 · External reference

Impact of noncardiac comorbidities on morbidity and mortality in a predominantly male population with heart failure and preserved versus reduced ejection fraction

10.1016/j.jacc.2011.11.040 · 2012 · External reference

Heart failure with preserved ejection fraction: treat now by treating comorbidities

10.1001/jama.300.4.431 · 2008 · External reference

A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation

10.1016/j.jacc.2013.02.092 · 2013 · External reference

Multiple common comorbidities produce left ventricular diastolic dysfunction associated with coronary microvascular dysfunction, oxidative stress, and myocardial stiffening

10.1093/cvr/cvy038 · 2018 · External reference

Proteomic evaluation of the comorbidity-inflammation paradigm in heart failure with preserved ejection fraction: results from the PROMIS-HFpEF study

10.1161/circulationaha.120.045810 · 2020 · External reference

Biomarker profiles in heart failure patients with preserved and reduced ejection fraction

10.1161/jaha.116.003989 · 2017 · External reference

Interleukin 6 and development of heart failure with preserved ejection fraction in the general population

10.1161/jaha.120.018549 · 2021 · External reference

Al-Kindi SG Inflammatory markers and risk of heart failure with reduced to preserved ejection fraction

10.1016/j.amjcard.2021.11.045 · 2022 · External reference

Health ABC Study Investigators. Inflammatory markers and incident heart failure risk in older adults: the Health ABC (Health, Aging, and Body Composition) study

10.1016/j.jacc.2009.12.045 · 2010 · External reference

10.1161/circheartfailure.122.010051

10.1161/circheartfailure.122.010051 · External reference

Prevalence and correlates of coronary microvascular dysfunction in heart failure and preserved ejection fraction: PROMIS-HFpEF

10.1093/eurheartj/ehy531 · 2018 · External reference

Untangling the pathophysiologic link between coronary microvascular dysfunction and heart failure with preserved ejection fraction

10.1093/eurheartj/ehab653 · 2021 · External reference

Cardiovascular magnetic resonance assessment of coronary flow reserve improves risk stratification in heart failure with preserved ejection fraction

10.1186/s12968-021-00807-3 · 2021 · External reference

The association of coronary microvascular dysfunction and cardiac maladaptation with clinical outcomes in heart failure with preserved ejection fraction: A prospective dynamic SPECT study

10.1016/j.ijcard.2025.133064 · 2025 · External reference

Protein kinase G modulates human myocardial passive stiffness by phosphorylation of the titin springs

10.1161/circresaha.108.184408 · 2009 · External reference

Myocardial stiffness in patients with heart failure and a preserved ejection fraction: contributions of collagen and titin

10.1161/circulationaha.114.013215 · 2015 · External reference

Low myocardial protein kinase G activity in heart failure with preserved ejection fraction

10.1161/circulationaha.111.076075 · 2012 · External reference

Deranged myofilament phosphorylation and function in experimental heart failure with preserved ejection fraction

10.1093/cvr/cvs353 · 2013 · External reference

cGMP-dependent protein kinase type I inhibits TAB1-p38 mitogen-activated protein kinase apoptosis signaling in cardiac myocytes

10.1074/jbc.m603416200 · 2006 · External reference

Omega-3 fatty acids prevent pressure overload-induced cardiac fibrosis through activation of cyclic GMP/protein kinase G signaling in cardiac fibroblasts

10.1161/circulationaha.110.971853 · 2011 · External reference

From systemic inflammation to myocardial fibrosis: the heart failure with preserved ejection fraction paradigm revisited

10.1161/circresaha.121.318159 · 2021 · External reference

Deletion of interleukin-6 attenuates pressure overload-induced left ventricular hypertrophy and dysfunction

10.1161/circresaha.116.308688 · 2016 · External reference

Interleukin 6 mediates myocardial fibrosis, concentric hypertrophy, and diastolic dysfunction in rats

10.1161/hypertensionaha.109.148635 · 2010 · External reference

Association of inflammatory-hematological biomarkers with hypertension and related comorbidities

10.3390/jcm15062279 · 2026 · External reference

Integrative inflammation-metabolism indicator for cardiovascular-kidney-metabolic syndrome: evaluating the c-reactive protein-triglyceride glucose index for risk stratification and progression across three national cohorts

10.1155/mi/8912366 · 2026 · External reference

Val-MARC Investigators. Valsartan, blood pressure reduction, and C-reactive protein: primary report of the Val-MARC trial

10.1161/01.hyp.0000226046.58883.32 · 2006 · External reference

Effects of initiating insulin and metformin on glycemic control and inflammatory biomarkers among patients with type 2 diabetes: the LANCET randomized trial

10.1001/jama.2009.1347 · 2009 · External reference

IL-6 trans-signaling is increased in diabetes, impacted by glucolipotoxicity, and associated with liver stiffness and fibrosis in fatty liver disease

10.2337/db23-0171 · 2023 · External reference

Effects of GLP-1 receptor agonists and dual GIP/GLP-1 receptor agonists on inflammatory and metabolic biomarkers in type 2 diabetes: a systematic review and meta-analysis

10.1111/dom.71106 · 2026 · External reference

The effect of sodium-glucose cotransporter-2 inhibitors on inflammatory biomarkers: A meta-analysis of randomized controlled trials

10.1111/dom.15586 · 2024 · External reference

Effects of finerenone on arterial stiffness and cardiorenal biomarkers in patients with type 2 diabetes and chronic kidney disease: a randomised placebo-controlled mechanistic trial (FIVE-STAR)

10.1186/s12933-025-03014-x · 2025 · External reference

Central adiposity or hypertension: which drives heart failure with a preserved ejection fraction?

2025 · External reference

Is type 2 diabetes a modifiable risk factor for the evolution and progression of heart failure with a preserved ejection fraction?

2025 · External reference

Chronic kidney disease in patients with heart failure with a preserved ejection fraction: the underlying role of visceral adiposity

2025 · External reference

The adipokine hypothesis of heart failure with a preserved ejection fraction: a novel framework to explain pathogenesis and guide treatment

10.1016/j.jacc.2025.06.055 · 2025 · External reference

Genetic architecture of heart failure with preserved versus reduced ejection fraction

10.1038/s41467-022-35323-0 · 2022 · External reference

Genome-wide association study meta-analysis provides insights into the etiology of heart failure and its subtypes

10.1038/s41588-024-02064-3 · 2025 · External reference

Circulating mediators linking cardiometabolic diseases to HFpEF: a mediation Mendelian randomization analysis

10.1186/s12933-025-02738-0 · 2025 · External reference

The impact of extra cardiac comorbidities on pressure volume relations in heart failure and preserved ejection fraction

10.1016/j.cardfail.2011.03.010 · 2011 · External reference

I-PRESERVE Investigators. Irbesartan in patients with heart failure and preserved ejection fraction

10.1056/nejmoa0805450 · 2008 · External reference

Sacubitril-valsartan as a treatment for apparent resistant hypertension in patients with heart failure and preserved ejection fraction

10.1093/eurheartj/ehab499 · 2021 · External reference

Systolic blood pressure in heart failure with preserved ejection fraction treated with sacubitril/valsartan

10.1016/j.jacc.2020.02.009 · 2020 · External reference

Systolic blood pressure and cardiovascular outcomes in heart failure with preserved ejection fraction: an analysis of the TOPCAT trial

10.1002/ejhf.1060 · 2018 · External reference

Spironolactone and resistant hypertension in heart failure with preserved ejection fraction

10.1093/ajh/hpx210 · 2018 · External reference

Empagliflozin in resistant hypertension and heart failure with preserved ejection fraction: the EMPEROR-Preserved trial

2025 · External reference

irrespective of blood pressure, improves outcomes in heart failure with preserved ejection fraction: the EMPEROR-Preserved trial

10.1093/eurheartj/ehac693 · 2023 · External reference

Raz I; SAVOR-TIMI 53 Steering Committee and Investigators. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus

10.1056/nejmoa1307684 · 2013 · External reference

10.1161/cir.0000000000000691

10.1161/cir.0000000000000691 · 2019 · External reference

SGLT-2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials

10.1016/s0140-6736(22)01429-5 · 2022 · External reference

EMPEROR-Preserved Trial Committees and Investigators. Empagliflozin for heart failure with preserved left ventricular ejection fraction with and without diabetes

10.1161/circulationaha.122.059785 · 2022 · External reference

Influence of type 2 diabetes on the effects of tirzepatide in patients with heart failure and a preserved ejection fraction with obesity: a prespecified stratification-based analysis

10.1016/j.jacc.2025.06.058 · 2025 · External reference

Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease

10.1056/nejmoa1306033 · 2013 · External reference

Correction of anemia with epoetin alfa in chronic kidney disease

10.1056/nejmoa065485 · 2006 · External reference

Daprodustat and heart failure in CKD

10.1681/asn.0000000000000321 · 2024 · External reference

STEP-HFpEF Trial Committees and Investigators. Inflammation in obesity-related HFpEF: The STEP-HFpEF program

10.1016/j.jacc.2024.08.028 · 2024 · External reference

Management of heart failure with preserved ejection fraction: 2026 ACC Expert Consensus Decision Pathway: A Report of the American College of Cardiology Solution Set Oversight Committee

2026 · External reference

Effect of tumor necrosis factor-alpha on endothelial and inducible nitric oxide synthase messenger ribonucleic acid expression and nitric oxide synthesis in ischemic and nonischemic isolated rat heart

10.1016/s0735-1097(03)00992-6 · 2003 · External reference

Activation of JNK and xanthine oxidase by TNF-alpha impairs nitric oxide-mediated dilation of coronary arterioles

10.1016/j.yjmcc.2005.11.010 · 2006 · External reference

Interaction of IL-6 and TNF-alpha contributes to endothelial dysfunction in type 2 diabetic mouse hearts

10.1371/journal.pone.0187189 · 2017 · External reference

High-sensitivity C-reactive protein is an independent marker of abnormal coronary vasoreactivity in patients with non-obstructive coronary artery disease

10.1016/j.ahj.2017.02.035 · 2017 · External reference

Inflammation and microvascular dysfunction in cardiac syndrome X patients without conventional risk factors for coronary artery disease

10.1016/j.jcmg.2012.12.011 · 2013 · External reference

Treatment with tumor necrosis factor inhibitors restores coronary microvascular function in young patients with severe psoriasis

10.1016/j.atherosclerosis.2016.05.036 · 2016 · External reference

Inhibition of interleukin-1 by anakinra improves vascular and left ventricular function in patients with rheumatoid arthritis

10.1161/circulationaha.107.731877 · 2008 · External reference

Effect of interleukin-6 inhibition on coronary microvascular and endothelial function in myocardial infarction

10.1136/heartjnl-2016-310875 · 2017 · External reference

Endothelium-dependent and independent coronary microvascular dysfunction in patients with heart failure with preserved ejection fraction

10.1002/ejhf.1671 · 2020 · External reference

Sex differences in proteomic correlates of coronary microvascular dysfunction among patients with heart failure and preserved ejection fraction

10.1002/ejhf.2435 · 2022 · External reference

Cardiac inflammation contributes to changes in the extracellular matrix in patients with heart failure and normal ejection fraction

10.1161/circheartfailure.109.931451 · 2011 · External reference

Endomyocardial biopsy characterization of heart failure with preserved ejection fraction and prevalence of cardiac amyloidosis

10.1016/j.jchf.2020.04.007 · 2020 · External reference

Myocardial microvascular inflammatory endothelial activation in heart failure with preserved ejection fraction

10.1016/j.jchf.2015.10.007 · 2016 · External reference

Nitric oxide decreases cytokine-induced endothelial activation. Nitric oxide selectively reduces endothelial expression of adhesion molecules and proinflammatory cytokines

10.1172/jci118074 · 1995 · External reference

Nitric oxide regulates vascular cell adhesion molecule 1 gene expression and redox-sensitive transcriptional events in human vascular endothelial cells

10.1073/pnas.93.17.9114 · 1996 · External reference

Long-term L-arginine supplementation improves small-vessel coronary endothelial function in humans

10.1161/01.cir.97.21.2123 · 1998 · External reference

Diastolic dysfunction is initiated by cardiomyocyte impairment ahead of endothelial dysfunction due to increased oxidative stress and inflammation in an experimental prediabetes model

10.1016/j.yjmcc.2019.10.005 · 2019 · External reference

Relevance of coronary microvascular flow impairment to long-term remodeling and systolic dysfunction in hypertrophic cardiomyopathy

10.1016/j.jacc.2005.10.050 · 2006 · External reference

The cardiac microvasculature in hypertension, cardiac hypertrophy and diastolic heart failure

10.2174/157016108785909779 · 2008 · External reference

Prevalence and importance of coronary microvascular dysfunction in patients with heart failure and reduced or mildly reduced ejection fraction

10.1136/openhrt-2025-003509 · 2025 · External reference

Impact of coronary microvascular dysfunction in heart failure with preserved ejection fraction: a meta-analysis

10.1002/ehf2.14626 · 2024 · External reference

Coronary microvascular dysfunction is associated with exertional haemodynamic abnormalities in patients with heart failure with preserved ejection fraction

10.1002/ejhf.2010 · 2021 · External reference

Coronary microvascular dysfunction and left heart filling pressures in patients with type 2 diabetes

10.1002/ehf2.14929 · 2024 · External reference

Nitrosative stress drives heart failure with preserved ejection fraction

10.1038/s41586-019-1100-z · 2019 · External reference

Phosphodiesterase 9A controls nitric-oxide-independent cGMP and hypertrophic heart disease

10.1038/nature14332 · 2015 · External reference

Nitric oxide-sensitive guanylyl cyclase stimulation improves experimental heart failure with preserved ejection fraction

10.1172/jci.insight.96006 · 2018 · External reference

PDE9A inhibition improves coronary microvascular rarefaction and left ventricular diastolic dysfunction in the ZSF1 rat model of HFpEF

10.1111/micc.12888 · 2024 · External reference

Enhanced cardiomyocyte function in hypertensive rats with diastolic dysfunction and human heart failure patients after acute treatment with soluble guanylyl cyclase (sGC) activator

10.3389/fphys.2020.00345 · 2020 · External reference

Protein phosphatase 5 regulates titin phosphorylation and function at a sarcomere-associated mechanosensor complex in cardiomyocytes

10.1038/s41467-017-02483-3 · 2018 · External reference

Decreased activity of the L-arginine-nitric oxide metabolic pathway in patients with congestive heart failure

10.1161/01.cir.99.16.2113 · 1999 · External reference

Nitrite therapy improves left ventricular function during heart failure via restoration of nitric oxide-mediated cytoprotective signaling

10.1161/circresaha.114.301475 · 2014 · External reference

Hypophosphorylation of the Stiff N2B titin isoform raises cardiomyocyte resting tension in failing human myocardium

10.1161/circresaha.108.193326 · 2009 · External reference

Effect of inorganic nitrite vs placebo on exercise capacity among patients with heart failure with preserved ejection fraction: The INDIE-HFpEF randomized clinical trial

10.1001/jama.2018.14852 · 2018 · External reference

NHLBI Heart Failure Clinical Research Network. Isosorbide mononitrate in heart failure with preserved ejection fraction

10.1056/nejmoa1510774 · 2015 · External reference

Inorganic nitrite to amplify the benefits and tolerability of exercise training in heart failure with preserved ejection fraction: the INABLE-Training trial

10.1016/j.mayocp.2023.08.031 · 2024 · External reference

VITALITY-HFpEF Study Group. Effect of vericiguat vs placebo on quality of life in patients with heart failure and preserved ejection fraction: The VITALITY-HFpEF Randomized Clinical Trial

10.1001/jama.2020.15922 · 2020 · External reference

Effect of Praliciguat on Peak Rate of Oxygen Consumption in Patients With Heart Failure With Preserved Ejection Fraction: The CAPACITY HFpEF Randomized Clinical Trial

10.1001/jama.2020.16641 · 2020 · External reference

Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial

10.1001/jama.2013.2024 · 2013 · External reference

Vericiguat in patients with worsening chronic heart failure and preserved ejection fraction: results of the SOluble guanylate Cyclase stimulatoR in heArT failurE patientS with PRESERVED EF (SOCRATES-PRESERVED) study

10.1093/eurheartj/ehw593 · 2017 · External reference

Tadalafil for treatment of combined postcapillary and precapillary pulmonary hypertension in patients with heart failure and preserved ejection fraction: a randomized controlled phase 3 study

10.1161/circulationaha.124.069340 · 2024 · External reference

Genetically proxied interleukin-6 signaling inhibition and heart failure risk

10.1016/j.jchf.2026.103057 · 2026 · External reference

Multiple plasma biomarkers for risk stratification in patients with heart failure and preserved ejection fraction

10.1016/j.jacc.2019.12.069 · 2020 · External reference

Circulating levels of tumor necrosis factor-alpha receptor 2 are increased in heart failure with preserved ejection fraction relative to heart failure with reduced ejection fraction: evidence for a divergence in pathophysiology

10.1371/journal.pone.0099495 · 2014 · External reference

Genth-Zotz S. Inflammatory pathways in patients with heart failure and preserved ejection fraction

10.1016/j.ijcard.2007.05.061 · 2008 · External reference

Identifying pathophysiological mechanisms in heart failure with reduced versus preserved ejection fraction

10.1016/j.jacc.2018.06.050 · 2018 · External reference

Inflammatory markers and risk of heart failure with reduced to preserved ejection fraction

10.1016/j.amjcard.2021.11.045 · 2022 · External reference

The clinical significance of interleukin-6 in heart failure: results from the BIOSTAT-CHF study

10.1002/ejhf.1482 · 2019 · External reference

Association between omentin-1 and heart failure with preserved ejection fraction in Chinese elderly patients

10.1002/clc.24181 · 2023 · External reference

Prevalence and associations of systemic inflammation in heart failure across the spectrum of ejection fraction

10.1016/j.jchf.2025.102712 · 2026 · External reference

Interleukin 6 mediates myocardial fibrosis, concentric hypertrophy, and diastolic dysfunction in rats

10.1161/hypertensionaha.109.148635 · 2010 · External reference

C-reactive protein overexpression exacerbates pressure overload-induced cardiac remodeling through enhanced inflammatory response

10.1161/hypertensionaha.110.158915 · 2011 · External reference

PPARalpha-NF-kappaB heterodimer mediates obesity-induced diastolic dysfunction through autocrine production of IL-6

10.1172/jci196238 · 2026 · External reference

Interleukin-6 deficiency attenuates angiotensin II-induced cardiac pathogenesis with increased myocyte hypertrophy

10.1016/j.bbrc.2017.10.119 · 2017 · External reference

Deletion of interleukin-6 attenuates pressure overload-induced left ventricular hypertophy and dysfunction

10.1161/circresaha.116.308688 · 2016 · External reference

Interleukin-6 blockade modulates monocyte recruitment to protect against diastolic dysfunction associated with inflammatory arthritis

10.1186/s13075-025-03700-x · 2026 · External reference

Tocilizumab treatment increases left ventricular ejection fraction and decreases left ventricular mass index in patients with rheumatoid arthritis without cardiac symptoms: assessed using 3.0 tesla cardiac magnetic resonance imaging

10.3899/jrheum.131540 · 2014 · External reference

Interleukin-6 blockade reduces salt-induced cardiac inflammation and fibrosis in subtotal nephrectomized mice

10.1152/ajprenal.00396.2021 · 2022 · External reference

IL-6 trans-signalling contributes to aldosterone-induced cardiac fibrosis

10.1093/cvr/cvy013 · 2018 · External reference

Interleukin-6 stimulates epithelial sodium channels in mouse cortical collecting duct cells

10.1152/ajpregu.00207.2009 · 2010 · External reference

Tumor necrosis factor-alpha mediates cardiac remodeling and ventricular dysfunction after pressure overload state

10.1161/circulationaha.106.643585 · 2007 · External reference

Interleukin-1beta disruption protects male mice from heart failure with preserved ejection fraction pathogenesis

10.1161/jaha.122.029668 · 2023 · External reference

Inflammatory macrophage interleukin-1β mediates high-fat diet-induced heart failure with preserved ejection fraction

10.1016/j.jacbts.2022.08.003 · 2022 · External reference

Toll-like receptor-2 mediates adaptive cardiac hypertrophy in response to pressure overload through interleukin-1beta upregulation via nuclear factor kappaB activation

10.1161/jaha.113.000267 · 2013 · External reference

gp130 plays a critical role in pressure overload-induced cardiac hypertrophy

10.1074/jbc.m100814200 · 2001 · External reference

Transmembrane tumor necrosis factor alpha attenuates pressure-overload cardiac hypertrophy via tumor necrosis factor receptor 2

10.1371/journal.pbio.3000967 · 2020 · External reference

Adipose tissue is a major source of interleukin-1 receptor antagonist: upregulation in obesity and inflammation

10.2337/diabetes.52.5.1104 · 2003 · External reference

IL-1 receptor antagonist serum levels are increased in human obesity: a possible link to the resistance to leptin?

10.1210/jcem.87.3.8351 · 2002 · External reference

Association between toll-like receptor polymorphisms and serum levels of tumor necrosis factor-alpha and its soluble receptors in obese children

2010 · External reference

Obesity Is a positive modulator of IL-6R and IL-6 expression in the subcutaneous adipose tissue: significance for metabolic inflammation

10.1371/journal.pone.0133494 · 2015 · External reference

Targeting IL-6 trans-signalling: past, present and future prospects

10.1038/s41577-023-00856-y · 2023 · External reference

Identifying plasma proteomic signatures from health to heart failure, across the ejection fraction spectrum

10.1038/s41598-024-65667-0 · 2024 · External reference

10.1038/s41598-022-24226-1

10.1038/s41598-022-24226-1 · External reference

Soluble tumor necrosis factor receptors and heart failure risk in older adults: Health, Aging, and Body Composition (Health ABC) Study

10.1161/circheartfailure.113.000344 · 2014 · External reference

Interleukin 6 signalling in heart failure with preserved and reduced ejection fraction

10.18087/cardio.2024.3.n2534 · 2024 · External reference

Interleukin-1 signalling inhibitors in heart failure with preserved and reduced ejection fraction

10.18087/cardio.2025.11.n2995 · 2025 · External reference

Transsignaling of interleukin-6 crucially contributes to atherosclerosis in mice

10.1161/atvbaha.111.229435 · 2012 · External reference

Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL)

10.1161/01.cir.0000124490.27666.b2 · 2004 · External reference

10.1161/01.cir.0000077913.60364.d2

10.1161/01.cir.0000077913.60364.d2 · 2003 · External reference

Anti-inflammatory therapy with canakinumab for the prevention of hospitalization for heart failure

10.1161/circulationaha.118.038010 · 2019 · External reference

Myocardial gene expression signatures in human heart failure with preserved ejection fraction

10.1161/circulationaha.120.050498 · 2021 · External reference

Omental and subcutaneous adipose tissues of obese subjects release interleukin-6: depot difference and regulation by glucocorticoid

1998 · External reference

Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-alpha, in vivo

1997 · External reference

Release of inflammatory mediators by human adipose tissue is enhanced in obesity and primarily by the nonfat cells: a review

10.1155/2010/513948 · 2010 · External reference

IL-6 biology: implications for clinical targeting in rheumatic disease

10.1038/nrrheum.2014.127 · 2014 · External reference

Impaired hepatic removal of interleukin-6 in patients with liver cirrhosis

10.1016/j.cyto.2010.06.013 · 2011 · External reference

Adipocyte-specific deletion of IL-6 does not attenuate obesity-induced weight gain or glucose intolerance in mice

10.1152/ajpendo.00206.2019 · 2019 · External reference

Causal role of adipose tissue-derived adipokines in the pathogenesis of heart failure with preserved ejection fraction: experimental demonstration as the basis for clinical targeting

10.1093/eurheartj/ehag029 · 2026 · External reference

Evolutionary history of the comorbidity-driven coronary microvascular endothelial inflammation hypothesis and its metamorphosis to the adipokine hypothesis of heart failure with a preserved ejection fraction

10.1016/j.jchf.2025.102822 · 2026 · External reference

IL-1 blockade in patients with heart failure with preserved ejection fraction

10.1161/circheartfailure.118.005036 · 2018 · External reference

Cardiovascular safety of tocilizumab versus etanercept in rheumatoid arthritis: a randomized controlled trial

10.1002/art.41095 · 2020 · External reference

Unresolved reference

2025 · External reference

Bayés-Genís A. Colchicine in acutely decompensated heart failure: the COLICA trial

10.1093/eurheartj/ehae538 · 2024 · External reference

Unresolved reference

External reference

Unresolved reference

External reference

Acute effects of myeloperoxidase inhibition on exercise hemodynamics in heart failure with preserved ejection fraction: a randomized clinical trial

10.1016/j.mayocp.2025.02.022 · 2025 · External reference

Myeloperoxidase inhibition in heart failure with preserved or mildly reduced ejection fraction: SATELLITE trial results

10.1016/j.cardfail.2023.04.003 · 2024 · External reference

Myeloperoxidase inhibition with mitiperstat in heart failure with preserved or mildly reduced ejection fraction: a randomized phase 2b trial

10.1038/s41591-026-04615-z · 2026 · External reference

Ziltivekimab in heart failure with preserved and mildly reduced ejection fraction: rationale and design of the ATHENA and HERMES trials

2026 · External reference

Novo Nordisk stops two cardiovascular trials of drug aimed at lowering inflammation

2026 · External reference